CDK6 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
This Target Evaluation Report for CDK6 is generated from PatSnap Life Sciences MCP data workflows, combining Target & Disease MCP biology context with Clinical Trials MCP validation and competitive signals.
For AI teams building biomedical agents, PatSnap Life Sciences MCP Servers provide structured retrieval across target biology, disease context, clinical trials, drug evidence, IP intelligence, and other R&D intelligence sources.
251 Direct drug records from Target & Disease MCP | 142 Development records in target context | 361 Disease associations captured | 1193 Clinical trial records from Clinical Trials MCP |
Explore PatSnap Life Sciences MCP Servers for AI agents
Executive View
CDK6 overlaps CDK4 but adds hematopoietic and differentiation biology
Target & Disease MCP describes CDK6 as a serine/threonine kinase controlling G1/S transition through RB1 phosphorylation and D-type cyclins, while also influencing differentiation, erythroid and hematopoietic proliferation, thymocyte development, neurogenesis, myeloid differentiation, and senescence.
Validation is strong but tightly linked to the CDK4/6 class
The MCP pull shows 251 direct drug records, 142 development records, and 361 disease associations. Clinical Trials MCP returned 1,193 records, reflecting broad class-level development.
Competition mirrors the CDK4/6 axis
Recent trial examples include T-DXd-based therapy followed by endocrine/HER2 blockade, trilaciclib plus immunochemotherapy, and T-DXd versus endocrine therapy in HER2-low/ultralow breast cancer. These data should be read in the context of cell-cycle and regimen sequencing.
IP and strategy view
CDK6-specific IP is most compelling when tied to hematopoietic effects, myeloprotection, differentiation biology, or selectivity distinct from CDK4.
Clinical Validation and Competitive Landscape
Clinical Trials MCP returned 1193 registered trial records connected to CDK6. The sample below is used as a directional competitive readout rather than a full regulatory review.
| Trial | Phase | Status |
|---|---|---|
| T-DXd followed by endocrine therapy plus dual HER2 blockade in HER2+/HR+ metastatic breast cancer | Phase 3 | Not yet recruiting |
| Trilaciclib combined with immunochemotherapy for recurrent/metastatic HNSCC | Phase 2 | Not yet recruiting |
| TRANSITION: T-DXd versus second-line endocrine therapy in HR+/HER2-low metastatic breast cancer | Phase 2 | Not yet recruiting |
R&D Strategy Recommendation
CDK6 should be evaluated through both oncology efficacy and hematopoietic biology. A winning profile needs more than class membership; it needs a reason to prefer CDK6 modulation.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
